Sign In
Buy AKRO
$54.65
+0 (+0%)
At Close: Mar 06, 2026
5 Biotech Stocks Worth Adding to Your Portfolio Now
10:25am, Tuesday, 23'rd Sep 2025
The volatile biotech industry has done reasonably well so far in 2025 amid the ongoing tariff saga. Most pharma/biotech bigwigs are now investing heavily in manufacturing plants/operations in the Unit
Akero Therapeutics, Inc. (AKRO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
01:07pm, Monday, 08'th Sep 2025
Akero Therapeutics, Inc. (NASDAQ:AKRO ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 10:45 AM EDT Company Participants Andrew Cheng - President, CEO & Director Conference
Has Akero Therapeutics (AKRO) Outpaced Other Medical Stocks This Year?
10:40am, Thursday, 28'th Aug 2025
Here is how Akero Therapeutics, Inc. (AKRO) and Stryker (SYK) have performed compared to their sector so far this year.
Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
07:00am, Thursday, 28'th Aug 2025
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious meta
Does Akero Therapeutics (AKRO) Have the Potential to Rally 59.14% as Wall Street Analysts Expect?
10:55am, Wednesday, 27'th Aug 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 59.1% in Akero Therapeutics (AKRO). While the effectiveness of this highly sought-after metric is questionable,
Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH Results support potential of efruxifermin (EFX) to reduce risk of fi
Are Medical Stocks Lagging Akero Therapeutics (AKRO) This Year?
10:41am, Tuesday, 12'th Aug 2025
Here is how Akero Therapeutics, Inc. (AKRO) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Akero (AKRO) Q2 Loss Narrows 6%
07:45am, Friday, 08'th Aug 2025
Akero (AKRO) Q2 Loss Narrows 6%
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
07:15am, Friday, 08'th Aug 2025
Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant
NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company")
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect
10:00am, Thursday, 05'th Jun 2025
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company")
NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company")
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
07:00am, Tuesday, 03'rd Jun 2025
SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious meta
NEW YORK CITY, NY / ACCESS Newswire / June 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company")
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation
10:05am, Thursday, 29'th May 2025
NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero"or "the Company")
